|
Volumn 13, Issue 7, 2016, Pages 398-
|
Urological cancer: Genetics of mCRPC tracked in ctDNA
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANDROGEN RECEPTOR;
CIRCULATING TUMOR DNA;
DNA;
ENZALUTAMIDE;
PROSTATE SPECIFIC ANTIGEN;
UNCLASSIFIED DRUG;
AR GENE;
BLOOD SAMPLING;
CANCER PROGNOSIS;
CANCER RESISTANCE;
CASTRATION RESISTANT PROSTATE CANCER;
COMPARATIVE GENOMIC HYBRIDIZATION;
COPY NUMBER VARIATION;
DNA DETERMINATION;
DNA SEQUENCE;
GENE LOSS;
GENE MUTATION;
GENETIC ASSOCIATION;
GENETIC SCREENING;
GENOMICS;
HUMAN;
MET GENE;
METASTASIS POTENTIAL;
MICROARRAY ANALYSIS;
NOTE;
ONCOGENE MYC;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE BIOPSY;
PROTEIN BLOOD LEVEL;
RB1 GENE;
TREATMENT DURATION;
TREATMENT RESPONSE;
GENETICS;
TUMOR EMBOLISM;
URINARY TRACT TUMOR;
CIRCULATING TUMOR DNA;
DNA, NEOPLASM;
HUMANS;
NEOPLASTIC CELLS, CIRCULATING;
UROLOGIC NEOPLASMS;
|
EID: 84973139159
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2016.91 Document Type: Note |
Times cited : (2)
|
References (0)
|